Conventional models of one-drug-one-disease are changing fast. Genetic research is at the forefront, fueling new discoveries that link diseases, therapies, and patient responses. Thermo Fisher genetic analysis solutions are helping to rapidly drive connections for multi-therapeutic approaches to treat complex human diseases.

When you partner with us on your journey from discovery to manufacturing you gain access to a breadth of technologies that enables to you to keep up with the development pace of therapeutics, interventions, and vaccines.

genetic-analysis-infographic22
Learn how genetic advancements can help to speed potential therapeutics to market


What's New?

jingfang-ju-phd

miRNA-based biomarkers and therapeutics for cancer

In this conversation with Dr. Jingfang Ju, he discusses advances in developing miRNA-based therapeutics and the value of gene expression analysis in discovering and verifying new miRNA-based biomarkers.

Download spotlight ›
QC-ex-vivo-manipulated-cell-lines-tissues-grey

QC for ex vivo manipulated cell lines and tissues

A variety of genetic analysis methods are valuable in ensuring that ex vivo human cells to be used for cell-based therapies are correctly identified, have the correct characteristics, and are free of contaminants.

Download whitepaper ›

 

darren-roberts-phd

Transcriptome analysis in tumors and response to therapy

In this conversation with Dr. Darren Roberts, he discusses challenges in conducting gene expression studies with DNA and RNA from  FFPE tumor tissues. He also explains the importance of selecting the right technology for each sample and stage in the process.

Download spotlight ›


Discovery

target-identification-pod1

Target identification

Drive new approaches to therapeutic development based on the impact of genetic and epigenetic targets on disease pathogenesis.

Gene expression analysis

Biomarker-discovery-pod2

Biomarker discovery

Propel studies of factors of prognostic risk, therapeutic response, and disease heterogeneity that may be influenced by genetic markers.

Gene sequencing

Single gene expression analysis

Expression signature analysis

miRNA analysis

Pathogen-characterization-pod2

Pathogen characterization

Uncover potential drivers of drug resistance and virulence from within microbial and viral strain genomes.

LOD testing

Pathogen gene and genome sequencing

Pathogen transcript analysis

16S gene sequencing

pathogen-interactions-pod2

Host/pathogen interactions

Explore the genetics and epigenetics that govern pathogenesis, cell tropism, and host immune response to pathogen invasion.

Host gene expression analysis

Pathogen gene expression

Host sensitivity genotyping


Screening and optimization

 

High-throughput-screening-pod1.jpg

High-throughput screening

Speed through large combinatorial plasmid, CRISPR, and fragment libraries to screen for desired drug target variants.

High throughput expression analysis

Expression vector sequencing

Target-validation-disease-modeling-pod

Target validation and disease modeling

Transform development of new therapeutic approaches with gene knock-down and knock-up investigations.

Sequence confirmation of genome edits

Gene expression change confirmation

Pathogen detection

Biomarker analysis

Preclinical-dosage-toxicology-safety-testing-pod
High-throughput-screening-pod1

High-throughput screening

Speed through large combinatorial plasmid, CRISPR, and fragment libraries to screen for desired drug target variants.

High throughput expression analysis

Expression vector sequencing


Process development

 

Microbial-identification-pod1

Microbial identification

Streamline development of new approaches to testing for microbes and mycoplasma.

16S gene sequencing

Mycoplasma detection

Targeted organism detection

Biological-sample-collection-pod

Biological sample collection, storage, and quality control

Ensure the integrity of cell lines for biotherapeutic studies.

Input sample identity cataloging, tissue archive authentication and  donor/host compatibility

Residual-vector-quantification-pod

Residual vector quantification

Drive studies of the impact of residual impurities and antibiotic resistance genes to assess quality and safety of biotherapeutics.

Sequence detection

Quantitative dPCR

 



Cell-line-quality-control-pod

Cell line quality control

Speed development of new approaches to cell-based therapeutics with authenticated cell lines and known sources of potential contamination.

STR matching

Mycoplasma detection

Expression system sequence integrity


Clinical trials

Therapeutic-efficacy-assessmentjpg

Therapeutic efficacy assessment

Transform possibilities for therapeutic efficacy assessment based on potential impacts of gene expression and pathogen invasion.

Pathogen detection

Biomarker confirmation

Toxicology-safety-assessment

Toxicology and safety assessment

Drive studies to reveal impacts of dosing, biotherapeutics, or multi-drug therapies on gene expression.

Tissue damage gene expression

Drug metabolizing enzyme gene expression

people-bkg-pod

Population stratification

Explore variability in responses to treatments, differentiate genetic vs. lifestyle contributors to disease, and investigate biomarkers for personalized therapies.

Genotypic stratification

Pharmacogenetic characterization

Companion diagnostic screening

Pharmacogenetic-screening_bkgrnd

Pharmacogenetic screening

Inspire new approaches to assessment of variability among drug metabolism genes and the relationships between genetic variations and drug response.

Pharmacogenomic profiling


Manufacturing

Production-quality-control-pod

Production quality control

Expand opportunities for advancements in quality control with genetic studies on microbial and residual vector impurities and unintended cell line proliferation.

16S gene sequencing

Mycoplasma detection

Targeted organism detection

Sequence detection

Quantitative dPCR

STR matching

Expression system sequence integrity

Antibiotic-drug-resistance-research-pod

Antibiotic and drug resistance research

Capture possible genetic drivers of antibiotic and drug resistance.  

Genotypic sequence drift

Targeted locus screening


Resources

covid-image-webinar

Biomarker analyses of post-COVID-19 neurological complications

In this webinar, Dr. Lynn Pulliam discusses her study that suggests possible neurological impacts of peripheral and neuroinflammation after COVID-19 infection.

Her study also reveals distinctions in possible neural damage associated with severity of COVID-19 infection.

View webinar ›
sanger-sequencing-quality-control

Sanger sequencing for quality control in AAV vector production

The use of AAV-mediated gene transfer is growing rapidly in basic and translational research as well as clinical gene therapy trials.

In this blog, we highlight the importance of quality control in recombinant AAV (rAAV) vector preparations and how DNA sequencing is key to qualitative and quantitative characterization of the product.

Read blog post ›
capillary-electrophoresis-drug-development

Wait, what? The role of capillary electrophoresis in drug development

Discover how capillary electrophoresis can be used to rapidly screen drugs and determine their mode of action when used in conjunction with in vitro assays.

High-throughput and multiplexing capabilities can be implemented to analyze potentially hundreds of samples in one plate within a few hours.

Read blog post ›
Style Sheet for Global Design System
Style Sheet for Komodo Tabs